Growth hormone-releasing hormone (GHRH) analogue — binds GHRH receptor on pituitary somatotrophs, stimulating GH pulse. Four amino acid substitutions vs native GHRH prevent DPP-IV degradation, extending half-life from 2 minutes to ~15–30 minutes. No albumin binding (distinguishing it from DAC version).
Studies have administered: 100mcg per injection, 2–3 injections daily in combination protocols
Potent GH pulse stimulation confirmed. Combination with ipamorelin or GHRP-2: synergistic GH amplitude increase 4–10x vs either alone. Physiological pulsatility preserved. More natural GH release pattern vs CJC-1295-DAC.
Injection site reactions; flushing sensation immediately post-injection; water retention; generally considered cleaner side effect profile than DAC version due to pulsatile nature
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Modified GRF(1-29) — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat